Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEAL1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 4	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7	AUG 27	USPATOLD now available on STN
NEWS 8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10	SEP 13	FORIS renamed to SOFIS
NEWS 11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 12	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16	OCT 19	BEILSTEIN updated with new compounds
NEWS 17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 18	NOV 19	WPIX enhanced with XML display format
NEWS 19	NOV 30	ICSD reloaded with enhancements
NEWS 20	DEC 04	LINPADOCDB now available on STN
NEWS 21	DEC 14	BEILSTEIN pricing structure to change
NEWS 22	DEC 17	USPATOLD added to additional database clusters
NEWS 23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 24	DEC 17	DGENE now includes more than 10 million sequences
NEWS 25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 29	JAN 02	STN pricing information for 2008 now available
NEWS 30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),

AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:01:03 ON 18 JAN 2008

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 15:01:15 ON 18 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JAN 2008 HIGHEST RN 1000264-70-9
DICTIONARY FILE UPDATES: 17 JAN 2008 HIGHEST RN 1000264-70-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10596851.str





chain nodes :
19 20 21 22 23 24 25 26 27 28 29 30 31 32 34
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
3-21 6-31 8-31 12-27 13-34 16-31 19-22 19-20 20-21 20-24 21-32 23-24
25-26 26-27 26-29 27-30 28-29
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-
15
15-16 16-17 17-18
exact/norm bonds :
12-27 13-14 13-18 13-34 14-15 15-16 16-17 16-31 17-18 19-20 20-21 20-24
21-32 25-26 26-27 26-29 27-30 28-29
exact bonds :
3-21 6-31 8-31 19-22 23-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 : 13 :

G1:Cb,Ak

G2:H,Cb,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 21:CLASS
22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS
32:CLASS 34:CLASS

L1 STRUCTURE UPLOADED

=> s l1 full
FULL SEARCH INITIATED 15:02:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 203 TO ITERATE

100.0% PROCESSED 203 ITERATIONS 90 ANSWERS
SEARCH TIME: 00.00.01

L2 90 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.82 179.03

FILE 'CAPLUS' ENTERED AT 15:02:19 ON 18 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 18 Jan 2008 VOL 148 ISS 4
FILE LAST UPDATED: 17 Jan 2008 (20080117/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l2 full
L3 2 L2

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:638860 CAPLUS Full-text
DOCUMENT NUMBER: 143:153402
TITLE: Preparation of diarylmethylpiperazines as δ receptor ligands for the treatment of pain
INVENTOR(S): Brown, William; Griffin, Andrew
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2005066148	A1	20050721	WO 2005-SE14	20050105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005204010	A1	20050721	AU 2005-204010	20050105
CA 2552851	A1	20050721	CA 2005-2552851	20050105
EP 1706393	A1	20061004	EP 2005-704688	20050105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
CN 1926122	A	20070307	CN 2005-80006254	20050105
BR 2005006702	A	20070502	BR 2005-6702	20050105
JP 2007517873	T	20070705	JP 2006-549190	20050105
IN 2006DN03738	A	20070420	IN 2006-DN3738	20060629
MX 2006PA07664	A	20060904	MX 2006-PA7664	20060703
NO 2006003619	A	20061009	NO 2006-3619	20060809
US 2007293502	A1	20071220	US 2007-596851	20070529
PRIORITY APPLN. INFO.:			SE 2004-27 A	20040109
			WO 2005-SE14 W	20050105

OTHER SOURCE(S): CASREACT 143:153402; MARPAT 143:153402
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = alkyl, alkenyl, cycloalkyl, etc.; R2 = H, alkyl, cycloalkyl, etc.; R3 = alkyl, cycloalkyl] and their pharmaceutically acceptable salts were prepared For example, N-alkylation of piperazine II (R1 =H) with bromoethyl Me ether afforded the hCL salt of claimed diarylmethylpiperazine II (R1 = CH2CH2OCH3) in 68% yield. In human δ receptor assays, certain examples of compds. I exhibited IC50 values ranging from 0.2-3.7 nM, with an average of 1 nM (sic).

IT 859634-99-4P 859635-00-0P 859635-01-1P
859635-02-2P 859635-03-3P 859635-04-4P
859635-05-5P 859635-06-6P 859635-07-7P
859635-08-8P 859635-09-9P 859635-10-2P
859635-11-3P 859635-12-4P 859635-13-5P
859635-14-6P 859635-15-7P 859635-16-8P
859635-17-9P 859635-18-0P 859843-90-6P
859843-91-7P 859843-92-8P 859843-93-9P
859843-94-0P 859843-95-1P 859843-96-2P
859843-97-3P 859843-98-4P 859843-99-5P
859844-00-1P 859844-01-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diarylmethylpiperazines as δ receptor ligands for treatment of pain)

RN 859634-99-4 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-

methoxyethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 859635-00-0 CAPLUS
CN Carbamic acid, [3-[(S)-(4-butyl-1-piperazinyl)[4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 859635-01-1 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl](4-pentyl-1-piperazinyl)methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 859635-02-2 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl](4-propyl-1-piperazinyl)methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 859635-03-3 CAPLUS
CN Carbamic acid, [3-[(S)-[4-(cyclopropylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 859635-04-4 CAPLUS
CN Carbamic acid, [3-[(S)-[4-(cyclobutylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester (9CI) (CA

INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 859635-05-5 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-methoxyethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859635-06-6 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-ethoxyethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859635-07-7 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(3-methoxypropyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859635-08-8 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-propyl-1-piperazinyl)methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859635-09-9 CAPLUS
CN Carbamic acid, [3-[(R)-(4-butyl-1-piperazinyl)[4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859635-10-2 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-pentyl-1-piperazinyl)methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859635-11-3 CAPLUS
CN Carbamic acid, [3-[(R)-[4-(cyclopropylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859635-12-4 CAPLUS
CN Carbamic acid, [3-[(R)-[4-(cyclobutylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859635-13-5 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-methoxyethyl)-1-piperazinyl]methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859635-14-6 CAPLUS
CN Carbamic acid, [3-[(R)-(4-butyl-1-piperazinyl)[4-

[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859635-15-7 CAPLUS
CN Carbamic acid, [3-[(R)-[4-(cyclopropylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859635-16-8 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-propyl-1-piperazinyl)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859635-17-9 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-ethyl-1-piperazinyl)methyl]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859635-18-0 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-methyl-1-piperazinyl)methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859843-90-6 CAPLUS
CN Carbamic acid, [3-[(S)-(4-butyl-1-piperazinyl)[4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 859843-91-7 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl](4-pentyl-1-piperazinyl)methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 859843-92-8 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-methoxyethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859843-93-9 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-propyl-1-piperazinyl)methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859843-94-0 CAPLUS
CN Carbamic acid, [3-[(R)-(4-butyl-1-piperazinyl)[4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859843-95-1 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-pentyl-1-piperazinyl)methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859843-96-2 CAPLUS
CN Carbamic acid, [3-[(R)-[4-(cyclopropylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859843-97-3 CAPLUS
CN Carbamic acid, [3-[(R)-[4-(cyclobutylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859843-98-4 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-methoxyethyl)-1-piperazinyl]methyl]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859843-99-5 CAPLUS
CN Carbamic acid, [3-[(R)-[4-(cyclopropylmethyl)-1-piperazinyl][4-[(diethylamino)carbonyl]phenyl]methyl]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859844-00-1 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-propyl-1-piperazinyl)methyl]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859844-01-2 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl](4-methyl-1-piperazinyl)methyl]phenyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 859635-21-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of diarylmethylpiperazines as δ receptor ligands for treatment of pain)

RN 859635-21-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(S)-[4-[(diethylamino)carbonyl]phenyl][3-[(methoxycarbonyl)amino]phenyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:412932 CAPLUS Full-text
DOCUMENT NUMBER: 140:423709
TITLE: Preparation of N-[4-(phenylpiperazinylmethyl)phenyl]carbamates for treatment of pain, anxiety, or gastrointestinal disorders
INVENTOR(S): Brown, William; Griffin, Andrew; Jones, Paul; Page, Daniel; Plobeck, Niklas; Walpole, Christopher
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041802	A1	20040521	WO 2003-SE1707	20031105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2502732	A1	20040521	CA 2003-2502732	20031105
AU 2003278665	A1	20040607	AU 2003-278665	20031105
EP 1562924	A1	20050817	EP 2003-770198	20031105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015995	A	20050927	BR 2003-15995	20031105
CN 1711252	A	20051221	CN 2003-80102831	20031105
JP 2006514002	T	20060427	JP 2004-549776	20031105
NZ 539484	A	20070531	NZ 2003-539484	20031105
IN 2005DN01579	A	20061229	IN 2005-DN1579	20050419
MX 2005PA04708	A	20050803	MX 2005-PA4708	20050502
US 2006122193	A1	20060608	US 2005-533654	20050504
US 7253173	B2	20070807		

ZA 2005003556	A	20060830	ZA 2005-3556		20050504
NO 2005002698	A	20050606	NO 2005-2698		20050606
US 2007254890	A1	20071101	US 2007-774935		20070709
PRIORITY APPLN. INFO.:			SE 2002-3303	A	20021107
			WO 2003-SE1707	W	20031105
			US 2005-533654	A1	20050504

OTHER SOURCE(S): MARPAT 140:423709
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1 = (un)substituted (hetero)aryl(alkyl); R2 and R3 = independently H or (un)substituted (cyclo)alkyl; or pharmaceutically acceptable salts, diastereomers, enantiomers, or mixts. thereof] were prepared as opioid δ receptor ligands. For example, 4-carboxybenzaldehyde was amidated with diethylamine using SOCl2 in CH2Cl2 to give N,N-diethyl-4-formylbenzamide (90%). Coupling of the amide with N-Boc-piperazine in the presence of benzotriazole in toluene, followed by reaction with 3-bromophenylzinc iodide in THF, afforded tert-Bu 4-[(3-bromophenyl)[4-[(diethylamino)carbonyl]phenyl]methyl]-1- piperazinecarboxylate (33%). Coupling with Me carbamate (62%) using xantphos, Cs2CO3, and Pd2(dba)3 in dioxane, deprotection (89%) with TFA in CH2Cl2, and chiral HPLC separation of the enantiomers provided (-)-[3-[[4-[(diethylamino)carbonyl]phenyl]-1-piperazinylmethyl]phenyl]carb amic acid Me ester. Reaction of the piperazine with benzaldehyde in the presence of NaBH(OAc)3 in CH2Cl2 gave (R)-II. In binding assays using human 293S cells expressing cloned human opioid receptors and neomycin resistance, (R)-II and ten other exemplified compds. exhibited strong binding to the δ receptor with IC50 values in the range of 0.25-0.74 nM and showed some activity toward the κ (IC50 = 247-1636 nM) and μ (IC50 = 93-1100 nM) receptors. In functional assays, (R)-II demonstrated δ receptor agonist activity by activating the binding of GTP to G-proteins. Thus, I and their pharmaceutical compns. are useful in therapy, in particular for the treatment of gastrointestinal disorders, anxiety, or pain (no data).

IT 691890-43-4P, 4-[[4-[(Diethylamino)carbonyl]phenyl][3-[(methoxycarbonyl)amino]phenyl]methyl]-1-piperazinecarboxylic acid 1,1-dimethylethyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of N-[(phenylpiperazinylmethyl)phenyl]carbamates as δ receptor agonists for treatment of pain, anxiety, or gastrointestinal disorders)

RN 691890-43-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-[(diethylamino)carbonyl]phenyl][3-[(methoxycarbonyl)amino]phenyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 691890-67-2P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(δ receptor agonist; preparation of N-[(phenylpiperazinylmethyl)phenyl]carbamates as δ receptor agonists for treatment of pain, anxiety, or gastrointestinal disorders)
RN 691890-67-2 CAPLUS
CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]methyl-, methyl ester, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



IT 691890-72-9P 691890-74-1P 691890-76-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(δ receptor agonist; preparation of N-[(phenylpiperazinylmethyl)phenyl]carbamates as δ receptor agonists for treatment of pain, anxiety, or gastrointestinal disorders)
RN 691890-72-9 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(4-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (5:9) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-71-8
CMF C28 H35 N5 O3 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691890-74-1 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(5-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (5:13) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-73-0
CMF C28 H35 N5 O3 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691890-76-3 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(5-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 691890-75-2
CMF C28 H35 N5 O3 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 691890-51-4P, (R)-Methyl [3-[[4-[(diethylamino)carbonyl]phenyl](4-benzylpiperazin-1-yl)methyl]phenyl]carbamate 691890-52-5P, (S)-Methyl [3-[[4-[(diethylamino)carbonyl]phenyl](4-benzylpiperazin-1-yl)methyl]phenyl]carbamate 691890-53-6P 691890-54-7P 691890-55-8P 691890-56-9P 691890-57-0P

691890-58-1P 691890-59-2P 691890-60-5P
691890-61-6P 691890-62-7P 691890-63-8P
691890-64-9P 691890-65-0P 691890-66-1P
691890-68-3P 691890-69-4P 691890-70-7P
691890-71-8P 691890-73-0P 691890-75-2P
691890-77-4P, Methyl [3-[[4-[(diethylamino)carbonyl]phenyl](4-benzylpiperazin-1-yl)methyl]phenyl]carbamate 691890-78-5P, Methyl [3-[[4-[(diethylamino)carbonyl]phenyl][4-(thien-2-ylmethyl)piperazin-1-yl]methyl]phenyl]carbamate 691890-79-6P, Methyl [3-[[4-[(diethylamino)carbonyl]phenyl][4-(thien-3-ylmethyl)piperazin-1-yl]methyl]phenyl]carbamate 691890-80-9P, Methyl [3-[[4-[(diethylamino)carbonyl]phenyl][4-(2-furylmethyl)piperazin-1-yl]methyl]phenyl]carbamate 691890-81-0P, Methyl [3-[[4-[(diethylamino)carbonyl]phenyl][4-(3-furylmethyl)piperazin-1-yl]methyl]phenyl]carbamate 691890-82-1P, Methyl [3-[[4-[(diethylamino)carbonyl]phenyl][4-(1H-imidazol-2-ylmethyl)piperazin-1-yl]methyl]phenyl]carbamate 691890-83-2P, Methyl [3-[[4-[(diethylamino)carbonyl]phenyl][4-(pyridin-2-ylmethyl)piperazin-1-yl]methyl]phenyl]carbamate 691890-84-3P, Methyl [3-[[4-[(diethylamino)carbonyl]phenyl][4-(pyridin-4-ylmethyl)piperazin-1-yl]methyl]phenyl]carbamate 691890-85-4P, Methyl [3-[[4-[(diethylamino)carbonyl]phenyl][4-(1,3-thiazol-2-ylmethyl)piperazin-1-yl]methyl]phenyl]carbamate 691890-86-5P 691890-87-6P
691890-88-7P 691890-89-8P 691890-90-1P
691890-91-2P 691890-92-3P 691890-93-4P
691890-94-5P 691890-95-6P 691890-96-7P
691890-97-8P 691890-98-9P 691890-99-0P
691891-00-6P 691891-01-7P 691891-02-8P
691891-03-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(δ receptor agonist; preparation of N-[(phenylpiperazinylmethyl)phenyl]carbamates as δ receptor agonists for treatment of pain, anxiety, or gastrointestinal disorders)

RN 691890-51-4 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 691890-52-5 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 691890-53-6 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 691890-54-7 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 691890-55-8 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(3-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 691890-56-9 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(3-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 691890-57-0 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 691890-58-1 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 691890-59-2 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(3-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 691890-60-5 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(3-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA

INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 691890-61-6 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(1H-imidazol-2-ylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 691890-62-7 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 691890-63-8 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 691890-64-9 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(4-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 691890-65-0 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(4-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 691890-66-1 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 691890-68-3 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(3-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 691890-69-4 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 691890-70-7 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(4-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 691890-71-8 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(4-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 691890-73-0 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(5-

thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 691890-75-2 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(5-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 691890-77-4 CAPLUS
CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 691890-78-5 CAPLUS
CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][4-(2-thienylmethyl)-

1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 691890-79-6 CAPLUS
CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][4-(3-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 691890-80-9 CAPLUS
CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][4-(2-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 691890-81-0 CAPLUS
CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][4-(3-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 691890-82-1 CAPLUS
CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][4-(1H-imidazol-2-ylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 691890-83-2 CAPLUS
CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][4-(2-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 691890-84-3 CAPLUS
CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][4-(4-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA

INDEX NAME)



RN 691890-85-4 CAPLUS
CN Carbamic acid, [3-[[4-[(diethylamino)carbonyl]phenyl][4-(2-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 691890-86-5 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (10:21) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-51-4
CMF C31 H38 N4 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691890-87-6 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (5:8) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-52-5
CMF C31 H38 N4 O3

Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691890-88-7 CAPLUS

CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (5:7) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-53-6
CMF C29 H36 N4 O3 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691890-89-8 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-54-7
CMF C29 H36 N4 O3 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691890-90-1 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(3-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (10:17) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-55-8
CMF C29 H36 N4 O3 S

Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691890-91-2 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(3-thienylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (5:7) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-56-9
CMF C29 H36 N4 O3 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691890-92-3 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-57-0

CMF C29 H36 N4 O4

Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691890-93-4 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (5:8) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-58-1
CMF C29 H36 N4 O4

Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691890-94-5 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(3-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-59-2
CMF C29 H36 N4 O4

Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691890-95-6 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(1H-imidazol-2-ylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate

(10:21) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-61-6
CMF C28 H36 N6 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691890-96-7 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-62-7
CMF C30 H37 N5 O3

Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691890-97-8 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(2-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (10:17) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-63-8
CMF C30 H37 N5 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691890-98-9 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(4-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (10:19) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-64-9
CMF C30 H37 N5 O3

Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691890-99-0 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(4-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (5:13) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-65-0
CMF C30 H37 N5 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691891-00-6 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(3-pyridinylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, hydrochloride (10:29) (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



●29/10 HCl

RN 691891-01-7 CAPLUS
CN Carbamic acid, [3-[(S)-[4-[(diethylamino)carbonyl]phenyl][4-(2-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, hydrochloride (2:3) (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



●3/2 HCl

RN 691891-02-8 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(4-thiazolylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 691890-70-7
CMF C28 H35 N5 O3 S

Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 691891-03-9 CAPLUS
CN Carbamic acid, [3-[(R)-[4-[(diethylamino)carbonyl]phenyl][4-(3-furanylmethyl)-1-piperazinyl]methyl]phenyl]-, methyl ester, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 691890-60-5
CMF C29 H36 N4 O4

Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



=> d his

(FILE 'HOME' ENTERED AT 15:01:03 ON 18 JAN 2008)

FILE 'REGISTRY' ENTERED AT 15:01:15 ON 18 JAN 2008
L1 STRUCTURE UPLOADED
L2 90 S L1 FULL

FILE 'CAPLUS' ENTERED AT 15:02:19 ON 18 JAN 2008
L3 2 S L2 FULL

=> log y
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST	12.82	191.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.60	-1.60

STN INTERNATIONAL LOGOFF AT 15:04:33 ON 18 JAN 2008